Forbes selected biotech companies in China & Hong Kong 2018, based on net income
This statistic shows the leading companies in biotechnology and drugs in mainland China and Hong Kong according to Forbes in 2018, based on net income value. According to Forbes Asia's 200 Best Under a Billion 2019 list, the net income of Chinese company Pharmablock Sciences, engaged in the drug molecular block designing and process development business, amounted to approximately 20 million U.S. dollars in 2018.